Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4GAG

Structure of the broadly neutralizing antibody AP33 in complex with its HCV epitope (E2 residues 412-423)

Summary for 4GAG
Entry DOI10.2210/pdb4gag/pdb
Related4GAJ 4GAY
DescriptorNEUTRALIZING ANTIBODY AP33 HEAVY CHAIN, NEUTRALIZING ANTIBODY AP33 LIGHT CHAIN, Genome polyprotein, ... (5 entities in total)
Functional Keywordsantibody fab, neutralizing antibody, hcv e2 binding, immune system
Biological sourceMus musculus
More
Total number of polymer chains3
Total formula weight49149.42
Authors
Potter, J.A.,Owsianka, A.,Angus, A.G.N.,Jeffery, N.,Matthews, D.,Keck, Z.,Lau, P.,Foung, S.K.H.,Taylor, G.L.,Patel, A.H. (deposition date: 2012-07-25, release date: 2012-10-10, Last modification date: 2024-11-20)
Primary citationPotter, J.A.,Owsianka, A.M.,Jeffery, N.,Matthews, D.J.,Keck, Z.Y.,Lau, P.,Foung, S.K.,Taylor, G.L.,Patel, A.H.
Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody.
J.Virol., 86:12923-12932, 2012
Cited by
PubMed Abstract: The E2 envelope glycoprotein of hepatitis C virus (HCV) binds to the host entry factor CD81 and is the principal target for neutralizing antibodies (NAbs). Most NAbs recognize hypervariable region 1 on E2, which undergoes frequent mutation, thereby allowing the virus to evade neutralization. Consequently, there is great interest in NAbs that target conserved epitopes. One such NAb is AP33, a mouse monoclonal antibody that recognizes a conserved, linear epitope on E2 and potently neutralizes a broad range of HCV genotypes. In this study, the X-ray structure of AP33 Fab in complex with an epitope peptide spanning residues 412 to 423 of HCV E2 was determined to 1.8 Å. In the complex, the peptide adopts a β-hairpin conformation and docks into a deep binding pocket on the antibody. The major determinants of antibody recognition are E2 residues L413, N415, G418, and W420. The structure is compared to the recently described HCV1 Fab in complex with the same epitope. Interestingly, the antigen-binding sites of HCV1 and AP33 are completely different, whereas the peptide conformation is very similar in the two structures. Mutagenesis of the peptide-binding residues on AP33 confirmed that these residues are also critical for AP33 recognition of whole E2, confirming that the peptide-bound structure truly represents AP33 interaction with the intact glycoprotein. The slightly conformation-sensitive character of the AP33-E2 interaction was explored by cross-competition analysis and alanine-scanning mutagenesis. The structural details of this neutralizing epitope provide a starting point for the design of an immunogen capable of eliciting AP33-like antibodies.
PubMed: 22993159
DOI: 10.1128/JVI.02052-12
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.8 Å)
Structure validation

229380

PDB entries from 2024-12-25

PDB statisticsPDBj update infoContact PDBjnumon